$ALC News

Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)

Barclays Maintains Equal-Weight on Alcon, Lowers Price Target to $78

Wells Fargo Maintains Overweight on Alcon, Lowers Price Target to $86

Mizuho Maintains Outperform on Alcon, Lowers Price Target to $85

Alcon Inc. (ALC) Q1 2026 Earnings Call Transcript

Baird Maintains Outperform on Alcon, Lowers Price Target to $90

BTIG Maintains Buy on Alcon, Lowers Price Target to $82

Alcon Q1 2026 Earnings Call Transcript

Needham Reiterates Buy on Alcon, Maintains $100 Price Target

Alcon Raises FY2026 Adj EPS Guidance from $3.35-$3.44 to $3.38-$3.47 vs $3.38 Est; Affirms FY2026 Sales Guidance of $10.835B-$11.041B vs $11.117B Est

Alcon Q1 Adj. EPS $0.85 Beats $0.81 Estimate, Sales $2.685B Miss $2.712B Estimate

Assessing Alcon (SWX:ALC) Valuation After Recent Share Price Weakness

Alcon Board Change And Vision Research Progress Shape Investor Expectations

US Startup PerZeption Inc. Announces Collaboration with Alcon Research

Alcon Announces Results of 2026 Annual General Meeting

Centurion Service Group and Auction Advisors announce major auction of assets from Fromer Eye Centers

How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential

National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others

Are Medical Stocks Lagging Alcon (ALC) This Year?

Why The Story Around Alcidion Group (ASX:ALC) Is Evolving While Fair Value Stays Steady